Method for treating usher syndrome and composition thereof
AssigneeEdigene Therapeutics (Beijing) Inc.
InventorsNengyin LIU, Zexuan YI, Pengfei YUAN, Yanxia ZHAO, Gangbin TANG
Life of this patent
Estimating the term…
Loading patent…
AssigneeEdigene Therapeutics (Beijing) Inc.
InventorsNengyin LIU, Zexuan YI, Pengfei YUAN, Yanxia ZHAO, Gangbin TANG
Estimating the term…
Provided is a method for targeted editing of target RNA containing a G to A mutation in a USH2A gene transcript based on LEAPER technology, comprising: introducing a construct of an adenosine deaminase recruiting RNA (arRNA) for editing the target RNA or a construct encoding said arRNA into a cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to the target RNA, and wherein the arRNA is capable of recruiting adenosine deaminase acting on RNA (ADAR), so that the target adenosine in the target RNA is deaminated, thereby performing in vivo editing of the base from A to I on RNA safely and effectively, repairing a pathogenic mutation site, and achieving the purpose of treating disease such as Usher syndrome.
A method for targeted editing of target RNA in a cell based on LEAPER technology, wherein the target RNA is an RNA containing a G to A mutation in a USH2A gene transcript, comprising:
An arRNA for targeted editing of the target RNA containing a G to A mutation in a USH2A gene transcript, comprising or consisting of a sequence selected from the group consisting of:
Dependencies are inferred from the claim text.